Conversion of Tislelizumab Combined With Chemotherapy in Unresectable Esophageal Squamous Cell Carcinoma
Clinical trial NCT05449483 · UNKNOWN
Trial details
- NCT number
- NCT05449483
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-11
- Primary completion
- 2023-06-30
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.